In:
International Journal of Cancer, Wiley, Vol. 146, No. 7 ( 2020-04), p. 2019-2026
Abstract:
What's new? In colorectal cancer (CRC), hepatic arterial infusion (HAI) chemotherapy may convert primarily unresectable CRC liver metastases (CLM) into resectable CLM. The risk of metastatic recurrence remains high, however, and molecular markers for long‐term therapeutic benefit are needed. In this prospective cohort study of patients who received oxaliplatin‐HAI, the authors assessed serum FLT3LG to monitor intratumoural immune activity. All patients experienced FLT3LG increase during therapy, but only those who experienced a rapid and substantial tumour‐directed immune response were alive 8–12 years later. Monitoring the immune response via serum FLT3LG may improve the selection of CLM patients for a curative‐intent ablation procedure.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8